Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia

Therapeutic Drug Monitoring

Volumn 28, Issue 6, 2006, Pages 800-806

  Dokmanovic, Lidija ^a   Urosevic, Jelena ^b   Janic, Dragana ^a   Jovanovic, Nada ^a   Petrucev, Branka ^b   Tosic, Natasa ^b   Pavlovic, Sonja ^b  

^a University Children's Hospital   (Serbia)

^b INSTITUTE OF MOLECULAR GENETICS AND GENETIC ENGINEERING   (Serbia)

Author keywords

Childhood acute lymphoblastic leukemia; Pharmacogenetics; Thiopurine S methyltransferase polymorphisms

Indexed keywords

MERCAPTOPURINE; METHOTREXATE; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; BLOOD SAMPLING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; SOUTHERN EUROPE; WILD TYPE; YUGOSLAVIA;

EID: 33845712657     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000249947.17676.92     Document Type: Conference Paper

References (57)

1. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta. 1978;85:323-333.
2. McLeod HL, Krynetski EY, Willimas JA, et al. Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics. 1995;5:281-286.
3. Krynetski EY, Tai HL, Yates CR, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics. 1996;6:279-290.
4. Lennard L, Lilleyman JS, Van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225-229.
5. Balis FM, Holcenberg JS, Poplack DG. General Principles of Chemotherapy. In: Pizzo AP, Poplack DG, eds. 4th ed. Philadelphia: JB Lippincott Co; 2001:210-245.
6. Evans WE, Horner M, Chu YO, et al. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltranferase-deficient child with acute lymphoblastic leukaemia. J Paediatr. 1991;119:985-989.
7. Ameyaw MM, Collie-Duguid ES, Powrie RH, et al. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999;8:367-370.
8. McLeod HL, Pritchard SC, Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics. 1999;9:773-776.
9. De la Moureyre SC, Debuysere H, Mustain B. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in European population. Br J Pharmacol. 1998;125:879-887.
10. Hon YY, Fessing MY, Pui CH, et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet. 1999;8:371-376.
11. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9:37-42.
12. Kumagai K, Hiyama K, Ishioka S, et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics. 2001;11:275-278.
13. Chang JG, Lee LS, Chen CM, et al. Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics. 2002;12:191-195.
14. Schaffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004;14:407-417.
15. Dervieux T, Meyer G, Barham R, et al. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy. Clin Chem. 2005;51:2074-2084.
16. Salavaggione OE, Wang L, Wiepert M, et al. Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics. 2005;15:801-815.
17. Krynetski EY, Schuetz JD, Galpin AJ, et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A. 1995;92:949-953.
18. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996;58:694-702.
19. Loennechen T, Yates CR, Fessing MY, et al. Isolation of a human thiopurine S-methyltransferase (TPMT) cDNA with a single nucleotide transition A719G (TPMT3C) and its association with loss of TPMT protein and catalytic activity in humans. Clin Pharmacol Ther. 1998;46:46-51.
20. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics. 2002;3:89-98.
21. Szumlanski C, Otternes D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 1996;15:17-30.
22. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
23. Schrappe M, Camitta B, Pui CH, et al. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000;14:2193-2194.
24. Pui CH, Relling MV, Evans WE. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2003;15:741-756.
25. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus. 1990;33:439-450.
26. Burger B, Zimmermann M, Mann G, et al. Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol. 2003;21:184-188.
27. Andersen JB, Szumlansky C, Weinshilboum RM, et al. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/metothrexate drug interaction in two patients with thiopurine methyltransferase deficiency. Acta Paediatr. 1998;87:108-111.
28. McLeod HL, Miller DR, Evans WE. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet. 1993;1341:1151.
29. Kaskas BA, Louis E, Hindorf U, et al. Safe treatment of thiopurine S-metyltransferase deficient Crohn's disease patients with azathioprine. Gut. 2003;52:140-142.
30. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008.
31. McLeod HL, Krynetski EY, Relling MV, et al. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia. 2000;14:567-572.
32. Schaffeler E, Stanulla M, Greil J, et al. A novel TPMT missense mutation associated with TPMT deficiency in a 5-year old boy with ALL. Leukemia. 2003;17:1422-1424.
33. Rocha JCC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005;105:4752-4758.
34. Relling MV, Pui CH, Cheng C, et al. Thiopurine metyltransferase in acute lymphoblastic leukemia. Blood. 2006;107:843-844.
35. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310-3322.
36. Stary J. Moderni lecba detske leukemie. Vox Pediatriae. 2003;9:16-20.
37. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia - current status and future perspectives. Lancet Oncol. 2001;2:597-607.
38. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997;126:608-614.
39. Evans WE. Comprehensive assessment of thiopurine S-methyltransferase (TPMT) alleles in three ethnic populations. J Pediatr Hematol Oncol. 2002;24:335-336.
40. Kurzawski M, Gawronska-Szklarz B, Drozdzik M. Frequency distribution of thiopurine S-methyltransferase alleles in a Polish population. Ther Drug Monit. 2004;26:541-545.
41. Indjova D, Atanasova S, Shipkova M, et al. Phenotypic and genotypic analysis of thiopurine S-methyltransferase polymorphism in the Bulgarian population. Ther Drug Monit. 2003;25:631-636.
42. Brouwer C, De Abreu RA, Keizer-Garritsen JJ, et al. Thiopurine methyltansferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects. Eur J Cancer. 2005;41:613-623.
43. McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukemia. Br J Haematol. 1999;105:696-700.
44. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651-662.
45. Rossi AM, Bianchi M, Guarnieri C, et al. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol. 2001;57:51-54.
46. von Ahsen N, Armstrong VW, Oellerch M. Rapid, long-range molecular haplotyping of thiopurine S-methyltransferase (TPMT) *3A, *3B, and *3C. Clin Chem. 2004;50:1528-1534.
47. McDonald OG, Krynetski EY, Evans WE. Molecular haplotyping of genomic DNA for multiple single-nucleotide polymorphisms located kilobases apart using long-range polymerase chain reaction and intramolecular ligation. Pharmacogenetics. 2002;12:93-99.
48. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19:2293-2301.
49. Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia. 1998;12:346-352.
50. Perentesis JP. Genetic predisposition and treatment-related leukemia. Med Pediatr Oncol. 2001;36:541-548.
51. Robison LL, Bhatia S. Late effects among survivors of leukemia and lymphoma during childhood and adolescence. Br J Haematol. 2003;122:345-359.
52. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumors after radiotherapy and antimetabolites. Lancet. 1999;354:34-39.
53. McBride KL, Gilchrist GS, Smithson WA, et al. Severe 6-thioguanine- induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency. J Pediatr Haematol Oncol. 2000;22:441-445.
54. Stanulla M, Schaffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA. 2005;293:1485-1489.
55. Relling MV, Hancook ML, Boyett JM, et al. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood. 1999;93:2817-2823.
56. McLeod HL, Relling MV, Liu Q, et al. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood. 1995;85:1897-1902.
57. Evans WE, Reling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.